Born leader

Born leader

16.09.2014 - David Veitch has been appointed as Chief Commercial Officer of Basilea Pharmaceutica International Ltd.

As a member of the management committee, David Veitch will be responsible for leading Basilea's commercial operations, including sales, marketing, pricing and market access. Veitch has over 25 years of international commercial experience in the pharmaceutical industry. Before joining Basilea, he led cross-functional organisations at the country and European level and was responsible for the launch of numerous brands across several therapeutic areas. From 1996 ­to 2011, he was President European Operations at Savient Pharmaceuticals. Veitch has also held various positions at Bristol-Myers Squibb UK and Europe. His last position at the company was Senior Vice President Europe, Middle-East and Asia, Marketing and Brand Commercialization, where he led the commercial organisation for the region with a focus on specialty care brands.

24.04.2014 Roche’s pRED unit has a new head of oncology and translational research.

Vanderbilt University Medical Center/Susan Urmy

William Pao, currently director at the Hematology-Oncology division and Personalised Cancer Medicine unit at Vanderbilt University Medical Center, will lead Roche’s discovery, translational medicine and early development of innovative oncology medicines. Pao, who has focused on academic clinical research in the past, is one of the world’s top oncology experts.

17.04.2014 Irish antibody developer Prothena Corporation plc has named Tara Nickerson as its Chief Business Officer.

Prothena Corp.

Previously she held the position of Head of Corporate and Business Development at the company, where she was instrumental during Prothena’s demerger from Elan and Prothena’s worldwide collaboration with Roche to develop and commercialise antibodies that target alpha-synuclein. Prior to Elan, Nickerson was a senior scientist at Celera Genomics (Axys Pharmaceuticals). 

15.04.2014 Geneva-based antibody developer Novimmune SA has appointed Andrew Oakley as its new CFO.


The finance expert has been the CFO and Vice President of Actelion Pharmaceuticals U.S., Inc. since January of 2003. Prior to that, he held executive positions in major multinational building material companies, and spent several years as an equity analyst with banks in Australia, the UK and the US. Oakley has been a member of the Australian Institute of Chartered Accountants since 1987.

08.04.2014 Germany’s Merck KGaA (Darmstadt) has hired the former head of Boehringer Ingelheim’s biopharmaceuticals development team to lead its biosimilar unit, which was set up in 2012.


Prior to the stint at Boehringer, Simon Sturge was CEO of Dutch biotech OctoPlus NV, and he also acted as CEO of Vernalis plc (UK). In the past, Sturge has held several roles of increasing seniority – from Business Development, Marketing and Operations to CEO at Lonza Biologics, as well as at Celltech Biologics and at AstraZeneca. The native of Britain was awarded the UK Mediscience CEO of the Year award in 2005. Sturge succeeds Thierry Hulot, who created Merck’s biosimilars unit and took over responsibility for Global Manufacturing & Supply for the Merck Serono division at the end of 2013. Along with Sturge, Merck has also strengthened its team internally with Friederike Rotsch, who has now taken over as chief legal advisor. 

27.03.2014 Ghent-based AgroSavfe BV has added to its management team Maria Abad-Molina new Head of Product & Business Development and Dr. Miguel De Bolle (Photo) as Head of Research.


While Bolle will head R&D to advance the company's Agrobody-technology platform for the development of innovative formulations for the sustainable use of crop protection products, Abad-Molina will be responsible for product development and registration at the company. A trained agronomical engineer who holds an Executive MBA, Abad--Molina has more than 20 years of experience in the crop protection and plant biotech-nology industries. Before joining the AgroSavfe management team, she was on the management team of BASF Plant Science subsidiary CropDesign, where she led global activities for placing plant protection products in the market, including the firm's top herbicide in terms of sales.

25.03.2014 British late-stage drug co-developer Avillion LLP appointed Dr. Allison Jeynes-Ellis to the post of Chief Executive Officer in February.

Dianna Bonner

The company’s cofounder and former CMO previously worked in senior roles at various pharmaceutical companies, including Wyeth, Bristol-Myers Squibb and Novartis. She has also acted as an independent consultant to many companies – including CAT and Genentech – as well as government bodies and medical research charities.

20.03.2014 In-vitro diagnostics instrumentation and software specialist Stratec Bio-medical AG (Birkenfeld) has appointed Claus Vielsack to its management board as Product Development Director.

Stratec Biomedical

Vielsack (46) has held various senior product development positions at Stratec since 1998. Before joining the Dx specialist, he held a number of different positions working as a programme manager in the development of chemical applications and software solutions.

18.03.2014 The European Medicines Agency (London) has named Dina Tsiambaou to head its IT Development Department.


She joins the Agency from Accenture, where she has had a long career defining, leading and delivering complex IT transformation and implementation projects. As with all EMA staff members, Tsiambaou will have to declare her interests in the pharmaceutical industry and divest herself of any shares she might own in pharmaceutical companies before beginning work at the Agency.

14.03.2014 Sartorius AG (Göttingen) has tapped the former CEO of analytical instruments provider Methrom’s US division to head marketing, sales and services at the firm’s Lab Products & Services Division.

Sartorius AG

Michael Melingo succeeds Dominique Baly, who is retiring. The new member of the Executive Committee – the highest operational management level in the Sartorius Group – brings in more than 30 years of experience in the industry. Prior to Methrom, the bioengineer worked as a sales and marketing executive with Baxter, Bio-Rad, Millipore and Waters in Europe and Asia.

12.03.2014 Medical device developer Vexxim SA (Toulouse) has named Sandrine Carle (43) to the post of Marketing Director.


Carle, who came in from Medtronics, will be responsible for the expansion of Vexxim’s business in new international markets. After graduating with a Master’s in Biomedical Engineering from Compiègne University of Technology (France) in 1994, she began her industry carreer at Aescula. In 2013, she obtained an Executive MBA from HEC Paris.

Vorherige Seite4/21Nächste Seite


All Events

Stock list

All quotes


  • ADDEX3.13 CHF4.68%
  • CO.DON3.15 EUR4.30%
  • BB BIOTECH146.25 EUR2.17%


  • WILEX2.35 EUR-5.24%
  • SANTHERA89.15 CHF-3.10%
  • EVOTEC2.93 EUR-2.33%


  • SANTHERA89.15 CHF31.2%
  • CO.DON3.15 EUR26.0%
  • PAION3.01 EUR24.4%


  • ADDEX3.13 CHF-22.3%
  • EVOTEC2.93 EUR-21.2%
  • MEDIGENE3.95 EUR-15.1%


  • SANTHERA89.15 CHF2117.7%
  • CO.DON3.15 EUR250.0%
  • PAION3.01 EUR189.4%


  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.67 EUR-40.6%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 17.09.2014

Current issue

All issues

Product of the week